Tag: advanced therapies
-
Uncertainties Surrounding the EU Joint Clinical Assessment: What do biotechs need to monitor
With the implementation of the new EU Health Technology Assessment (HTA) Regulation just four months away, uncertainties remain. The most important ones we will look at in this short clip, before exploring strategies for success the next time.
-
Nononsense EU JCA
No-nonsense EU HTA Introducing bit-sized no-nonsense insights about the EU HTA Regulation, Joint Clinical Assessment, Joint Scientific Consultations, etc etc. In a series of posts, there will be Q&A, process overviews, insights about preparedness, uncertainties and unknowns, as well as news as they happen in the continuing implementation phase. Got a question or query to…
-
Apersy’s 1st anniversary
I started with the vision to create independent market access services that can support health tech companies through the challenges of precision medicine, complex treatment regimens and care approaches that blur the boundaries between device, pharmaceuticals and digital.
-
February 2023 Monthly Reading List
Selected reads from recent press or publications in the disruptive value, commercial and reimbursement space.
-
November Market Access news recap
November market access news recap For the November recap a few news snippets from the pharma and digital health world: RWE collection in Germany, the Hemgenix gene therapy, early value assessment in England as well as the dynamic French digital health policy landscape. … as usual, three minutes of your time …
-
France PLFSS 2023: Social security financing bill puts pressure on medicine pricing
France PLFSS 2023: Social security financing bill puts pressure on medicine pricing The draft of the French social security financing law for the year to come (PLFSS 2023) includes a few proposals that could have an impact on innovative medicine pricing, including ATMPs and products eligible for the “European price”, meaning products that have demonstrated…